Abstract 5929
Background
Data for metastatic soft tissue sarcoma (STS) is sparse from developing countries. Pazopanib has demonstrated promising activity in the management of this disease. This study was carried out in the dedicated sarcoma medical oncology clinic in a tertiary referral center of Western India.
Methods
This is a retrospective analysis of prospective database from adult sarcoma medical oncology clinic at Tata Memorial Center, Mumbai from January 2035 to December 2018. The patients were provided holistic care through involvement of palliative care team, government fundings, local NGOs and sarcoma support groups. All statistical calculations were done using SPSS version 20.
Results
A total of 314 patients diagnosed with metastatic STS were registered in the dedicated medical oncology sarcoma clinic, 72% were males and median age 46 (16-79) years. Out of 314 patients, 60 (19%) patients received Pazopanib at some point of time during their treatment. Most common histology was synovial sarcoma (28%), leiomyosarcoma (26%), unspecified high grade spindle cell sarcoma (19%) and alveolar soft part sarcoma (12%). The median follow up duration was 18 (4-41) months. Median lines of prior therapy were 2 (0-2). Among 42 evaluable patients, there were 24% partial responses, 48% stable disease and 28% progressive disease. Median progression free survival was 5 (95% CI 3-7.3) months and median overall survival was 11 (95% CI 6.8-16.2) months. Important adverse events (>grade 1) included hand foot syndrome (10%), diarrhea (10%), hypothyroidism (10%), fatigue (8%) and hyperbilirubinemia/transaminitis (8%). Notably 50% patients required dose reduction and median dose was 600(200-800) mg daily.
Conclusions
Pazopanib was found to be a feasible treatment option for metastatic STS in India with internationally comparable outcomes. Median tolerated dose was lower than the standard 800 mg dose. Outcomes could be improved due to dedicated clinic with availability of targeted therapy with government help and local NGOs. This model of providing holistic care can be replicated in rare tumors in developing countries.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Tata Memorial Hospital, Mumbai.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4369 - Biomarker testing of lung cancer in Spain
Presenter: Delvys Rodriguez Abreu
Session: Poster Display session 1
Resources:
Abstract
603 - Mendelian Randomization Study of Alzheimer's Disease and Lung Cancer
Presenter: Huaqiang Zhou
Session: Poster Display session 1
Resources:
Abstract
4462 - Spanish registry of thoracic tumors (TTR): Interim analyses of comorbidities, risk associations, personal and family history of cancer
Presenter: Rafael Lopez Castro
Session: Poster Display session 1
Resources:
Abstract
3957 - Pleural effusion TGF-beta is highly diagnostic and prognostic in malignant pleural mesothelioma
Presenter: Paul Stockhammer
Session: Poster Display session 1
Resources:
Abstract
3583 - Immune microenvironment modulation by p14/ARF in Malignant Pleural Mesothelioma
Presenter: Giulia Pasello
Session: Poster Display session 1
Resources:
Abstract
4255 - Tumor Treating Fields plus chemotherapy for first-line malignant pleural mesothelioma (MPM): radiological responses in the STELLAR trial
Presenter: Federica Grosso
Session: Poster Display session 1
Resources:
Abstract
1803 - Effects of Tumor Treating Fields (TTFields; 150 kHz) and Cisplatin or Pemetrexed Combination Therapy on Mesothelioma cells In Vitro and In Vivo
Presenter: Mijal Munster
Session: Poster Display session 1
Resources:
Abstract
2660 - Real world use of systemic therapy in elderly patients with malignant pleural mesothelioma (MPM)
Presenter: Susana Cedres
Session: Poster Display session 1
Resources:
Abstract
3150 - Pemetrexed/Cisplatin versus Gemcitabine/Cisplatin as first-line treatment for Egyptian patients with malignant pleural mesothelioma
Presenter: Mohamed Alorabi
Session: Poster Display session 1
Resources:
Abstract
4319 - Accuracy of pathologic evaluation for thymic epithelial tumors in an Italian reference Centre
Presenter: Giulia Galli
Session: Poster Display session 1
Resources:
Abstract